In the following video, Motley Fool health-care analyst David Williamson takes a look at Mylan , and its recent agreement to acquire generic injectable products maker Agila Specialties from Strides Arcolab, for $1.6 billion in cash. David tells investors how this deal doubles Mylan's exposure to the high-margin biosimilars market, just as the Affordable Care Act is creating provisions for a pathway to bring biosimilars through an approval process and out to market.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Mylan Just Got More Interesting originally appeared on Fool.com.David Williamson owns shares of Pfizer. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.